Hyperlipidemia Management in CKD
Objectives for Learning
- What are the latest guidelines for managing patients with hyperlipidemia
- What is the latest in hyperlipidemia management in patients with CKD?
- What is the impact of the SHARP study in patients with CKD
- What is new on the horizon in lipid management: raising HDL with CETP inhibitors
Our Expert Faculty:
- Dr. Lawrence Leiter, Endocrinologist (St. Michael's Hospital, University of Toronto)
- Dr. Phil McFarlane, Nephrologist (St. Michael's Hospital, University of Toronto)
- Dr. Subodh Verma, Cardiac Surgeon (St. Michael's Hospital, University of Toronto)
Select a presentation | ||
![]() | ![]() | ![]() |
This program was supported by an unrestricted grant from Merck Canada. Merck Canada was not involved in the content development